Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis

被引：0
|
作者：
Schwarzer, A. [1 ]
Schulte, C. [2 ]
Fries, S. [3 ]
Cavo, M. [4 ]
Tsukada, N. [5 ]
Tekle, C. [6 ]
Manasanch, E. E. [7 ]
Knauf, W. [8 ]
机构：
[1] Onkopraxis Probstheida, Leipzig, Germany
[2] Gemeinsch Praxis Hamatol & Onkol, Dortmund, Germany
[3] Onkol Schwerpunktpraxis, Bamberg, Germany
[4] Univ Bologna, IRCCS Azienda Osped, Ist Ematol, Bologna, Italy
[5] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
[6] Sanofi, Cambridge, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[8] Centrum Hamatol & Onkol Bethanien, Frankfurt, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1109
引用
收藏
页码：316 / 316
页数：1
相关论文
共 50 条
  • [21] Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Powers Happ, Lindsey
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [23] Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/Refractory Multiple Myeloma (rrMM) Patients
    Shao, Changxia
    Monberg, Matthew
    Cao, Xiting
    Zhou, Wei
    Zhong, Yichen
    Marinello, Patricia
    BLOOD, 2016, 128 (22)
  • [24] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
  • [25] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
  • [26] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [27] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [28] Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
    Dileo, Rachel
    Mewawalla, Prerna
    Patrus, Gina
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2024, 144 : 4742 - 4743
  • [29] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [30] Real-World Experience With Talquetamab Clinical Management in Relapsed Refractory Multiple Myeloma (RRMM): A Qualitative Study of US Healthcare Providers
    Schinke, Carolina
    Dhakal, Binod
    Mazzoni, Sandra
    Shenoy, Samantha
    Scott, Sara
    Richards, Tiffany
    Le, Hoa
    DeBrosse, Amalia
    Okorozo, Peter
    McDowell, Rachel
    Patel, Saurabh
    Bunn, Jonathan
    Hawks, Kelly
    Zhang, Xinke
    Rodriguez-Valdes, Cesar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S265 - S266
12345